IDH Mutant Cholangiocarcinoma: Pathogenesis, Management, and Future Therapies

IDH Mutant Cholangiocarcinoma: Pathogenesis, Management, and Future Therapies

Mutations in isocitrate dehydrogenase (IDH) genes are among the most frequently encountered molecular alterations in cholangiocarcinoma (CCA). These neomorphic point mutations endow mutant IDH (mIDH) with the ability to generate an R-enantiomer of 2-hydroxyglutarate (R2HG), a metabolite that drives...

Full description

Bibliographic Details
Main Authors: Alexander Bray, Vaibhav Sahai
Format: Article
Language:English
Published: MDPI AG 2025-01-01
Series:Current Oncology
Subjects:
cholangiocarcinoma
mutant isocitrate dehydrogenase
targeted therapy
ivosidenib
2-hydroxyglutarate
R2HG
Online Access:https://www.mdpi.com/1718-7729/32/1/44

Internet

https://www.mdpi.com/1718-7729/32/1/44

Similar Items